BiotechTube
MediMabBio

MediMabBio

Cambridge, United Kingdom· Est.
medimabbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

MediMabBio is a private, pre-clinical stage biotech pioneering precision immuno-oncology and autoimmune therapies through a rational protein design platform. The company, co-led by founders with deep expertise from Oxford, KAIST, and Samsung, focuses on engineering novel monoclonal antibodies and cytokine-antibody fusion proteins to overcome limitations of current immunotherapies. With a recent Series B funding of KRW 25.6 billion (approx. $18-20M), a growing pipeline, and a collaborative open-innovation business model, MediMabBio is positioning itself as a global player in next-generation biologics. Its research is supported by partnerships with academic institutions and industry players like Celltrion and Charles River.

OncologyAutoimmune Diseases

Technology Platform

Rational protein design platform for engineering novel monoclonal antibodies and cytokine-antibody fusion proteins with enhanced specificity, potency, and safety. Focuses on targeting novel epitopes, precise T cell engagement, and targeted cytokine delivery.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The large and growing immuno-oncology market, combined with significant unmet need for safer, more effective therapies, presents a major opportunity.
MediMabBio's differentiated platform, particularly its cytokine-antibody fusion approach, could address the toxicity limitations of traditional cytokines and capture value in a promising niche.
Successful validation of its lead candidate could attract lucrative partnership deals with larger pharma companies seeking next-generation immuno-oncology assets.

Risk Factors

The company faces high developmental risk as a pre-clinical biotech, with no guarantee its candidates will succeed in human trials.
It operates in the intensely competitive and scientifically complex fields of immuno-oncology and cytokine engineering, where differentiation is challenging.
Its partnership-dependent business model introduces execution risk if key collaborations are not secured or fail to progress.

Competitive Landscape

MediMabBio competes in the crowded immuno-oncology space against large pharma (e.g., Merck, Roche, BMS) and numerous biotechs developing checkpoint inhibitors, bispecifics, and cytokine therapies. Its specific focus on rationally designed cytokine fusions and novel epitope targeting places it against specialized players like Werewolf Therapeutics, Senti Bio, and other modality-focused biotechs. Success will hinge on demonstrating clear preclinical and clinical differentiation from these established and emerging competitors.

More companies in United Kingdom →